Patents by Inventor Ditte Riber

Ditte Riber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20240141010
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: January 9, 2024
    Publication date: May 2, 2024
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Wolfgang RIST
  • GLUCAGON ANALOGUES
    Publication number: 20240067696
    Abstract: The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation.
    Type: Application
    Filed: September 21, 2023
    Publication date: February 29, 2024
    Applicant: Zealand Pharma A/S
    Inventors: Ditte RIBER, Lise GIEHM
  • Acylated glucagon analogues
    Patent number: 11884713
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: January 30, 2024
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Wolfgang Rist
  • Optimized GIP Peptide Analogues
    Publication number: 20230416330
    Abstract: Disclosed are glucose-dependent insulinotropic peptide (GIP) -derived peptide analogues which are antagonists of the GIP receptor. These GIP peptide analogues are optimized by comprising amino acid substitutions A13Aib and/or N24E, and are fatty acid conjugated with/without a linker, so to have improved solubility and/or physical stability.
    Type: Application
    Filed: December 3, 2020
    Publication date: December 28, 2023
    Inventors: Mette Marie ROSENKILDE, Alexander Hovard SPARRE-ULRICH, Ditte RIBER, Samra Joke SANNI
  • Glucagon analogues
    Patent number: 11795204
    Abstract: The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: October 24, 2023
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Lise Giehm
  • Modified GIP Peptide Analogues
    Publication number: 20220298218
    Abstract: Disclosed are glucose-dependent insulinotropic peptide (GIP)-derived peptide analogues which are antagonists of the GIP receptor. These GIP peptide analogues are modified by comprising one or more individual amino acid substitutions and are fatty acid conjugated with/without a linker, so to have improved antagonistic activity and improved pharmacokinetic profile.
    Type: Application
    Filed: December 3, 2019
    Publication date: September 22, 2022
    Inventors: Alexander Hovard SPARRE-ULRICH, Bjørn Behrens SIVERTSEN, Ditte RIBER, Mette Marie ROSENKILDE
  • Acylated glucagon analogue
    Patent number: 11274136
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: March 15, 2022
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Leo Thomas
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20220073583
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: July 7, 2021
    Publication date: March 10, 2022
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Wolfgang RIST
  • Modified GIP Peptide Analogues
    Publication number: 20220025010
    Abstract: Disclosed are glucose-dependent insulinotropic peptide (GIP)-derived peptide analogues which are antagonists of the GIP receptor. These GIP peptide analogues are modified by comprising one or more individual amino acid substitutions and are fatty acid conjugated with/without a linker, so to have improved antagonistic activity and improved pharmacokinetic profile.
    Type: Application
    Filed: December 3, 2019
    Publication date: January 27, 2022
    Inventors: Alexander Hovard SPARRE-ULRICH, Bjørn Behrens SIVERTSEN, Ditte RIBER, Mette Marie ROSENKILDE
  • GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS
    Publication number: 20210363213
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 25, 2021
    Inventors: Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torben ØSTERLUND, Kate HANSEN, Lene JESSEN
  • Glucagon-GLP-1-GIP triple agonist compounds
    Patent number: 11111285
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: September 7, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Ditte Riber, Anne Pernille Tofteng Shelton, Torben Østerlund, Kate Hansen, Lene Jessen
  • Acylated glucagon analogues
    Patent number: 11091528
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: August 17, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Wolfgang Rist
  • Glucagon analogues and methods of use
    Patent number: 11034747
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: June 15, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht
  • GLUCAGON ANALOGUES
    Publication number: 20200207825
    Abstract: The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation.
    Type: Application
    Filed: September 11, 2019
    Publication date: July 2, 2020
    Inventors: Ditte RIBER, Lise GIEHM
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20200157168
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: September 12, 2019
    Publication date: May 21, 2020
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Wolfgang RIST
  • ACYLATED GLUCAGON ANALOGUE
    Publication number: 20200087372
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: May 13, 2019
    Publication date: March 19, 2020
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Leo THOMAS
  • Acylated glucagon analogues
    Patent number: 10457714
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: October 29, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Wolfgang Rist
  • Glucagon analogues
    Patent number: 10442847
    Abstract: The present invention relates to glucagon analogs and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogs suitable for use in a liquid formulation.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: October 15, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Lise Giehm
  • GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS
    Publication number: 20190270789
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Application
    Filed: October 4, 2018
    Publication date: September 5, 2019
    Inventors: Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torben ØSTERLUND, Kate HANSEN, Lene JESSEN
  • Acylated glucagon analogue
    Patent number: 10336802
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: July 2, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Leo Thomas